RxDoctor Payments Data

Sylvia Zuniga Barboni, MD

Neurology · Palm Beach Gardens, FLNPI 1073578209

Payments from drug & device makers

$9,066in general payments, 2019–2025

Across 492 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$802
  • Amgen$605
  • Novartis$580
  • Sanofi$511
  • Supernus Pharmaceuticals, Inc.$492
  • plus $5K from 41 others

What the payments were for

  • Speaking & faculty fees$771%
  • Food & beverage$8,98899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,066 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$320,604
Medicare patients
626
Services billed
4,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$121,161
NuplazidPimavanserin Tartrate12$49,417
Emgality PenGalcanezumab-Gnlm19$13,663
Gabapentin367$5,677
Memantine Hcl111$3,697
Levetiracetam54$2,554
Pregabalin121$2,456
Levetiracetam ErLevetiracetam22$2,319
Primidone50$1,861
Donepezil Hcl161$1,753
Escitalopram Oxalate109$1,554
Carbidopa-LevodopaCarbidopa/Levodopa83$1,391
Duloxetine Hcl49$807
Quetiapine Fumarate23$667
Trazodone Hcl76$553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$47$121,16112 claims
Acadia Pharmaceuticals IncNuplazid$184$49,41712 claims
Upsher-smith Laboratories LLCTopiramate$72$45729 claims
Lilly USA, LLCOlanzapine$370$34611 claims
Almatica Pharma LLCSertraline Hcl$51$16911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →